Immunoinformatics approach for design novel multi-epitope prophylactic and therapeutic vaccine based on capsid proteins L1 and L2 and oncoproteins E6 and E7 of human papillomavirus 16 and human papillomavirus 18 against cervical cancer.

Autor:	Ryan N; Medical Study Program, Faculty of Medicine, Universitas Tanjungpura, Pontianak, Indonesia., Pratiwi SE; Department of Biology and Pathobiology, Faculty of Medicine, Universitas Tanjungpura, Pontianak, Indonesia., Mardhia M; Department of Microbiology, Faculty of Medicine, Universitas Tanjungpura, Pontianak, Indonesia., Ysrafil Y; Department of Pharmacotherapy, Faculty of Medicine, Universitas Palangka Raya, Palangka Raya, Indonesia., Liana DF; Department of Microbiology, Faculty of Medicine, Universitas Tanjungpura, Pontianak, Indonesia., Mahyarudin M; Department of Microbiology, Faculty of Medicine, Universitas Tanjungpura, Pontianak, Indonesia.
Jazyk:	angličtina
Zdroj:	Osong public health and research perspectives [Osong Public Health Res Perspect] 2024 Aug; Vol. 15 (4), pp. 307-328. Date of Electronic Publication: 2024 Jul 23.
DOI:	10.24171/j.phrp.2024.0013
Abstrakt:	Background: This study aimed to identify the optimal protein construction for designing a multi-epitope vaccine with both prophylactic and therapeutic effects against cervical cancer, utilizing an immunoinformatics approach. The construction process involved using capsid epitopes L1 and L2, as well as oncoproteins E5, E6, and E7 from human papillomavirus (HPV) types 16 and 18. Methods: An experimental in silico analysis with an immunoinformatics approach was used to develop 2 multi-epitope vaccine constructs (A and B). Further analysis was then conducted to compare the constructs and select the one with the highest potential against cervical cancer. Results: This study produced 2 antigenic, non-allergenic, and nontoxic multi-epitope vaccine constructs (A and B), which exhibited the ideal physicochemical properties for a vaccine. Further analysis revealed that construct B effectively induced both cellular and humoral immune responses. Conclusion: The multi-epitope vaccine construct B for HPV 16 and 18, designed for both prophylactic and therapeutic purposes, met the development criteria for a cervical cancer vaccine. However, these findings need to be validated through in vitro and in vivo experiments.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu